Skip to content
Biotron Limited
  • Home
  • About Us
    • Board of Directors
    • Management Team
  • Technology
    • Clinical programs
    • Non-clinical programs
    • Intellectual property
  • News/Resources
    • Newsletters
    • In the news
    • Scientific Presentations
    • Scientific Publications
  • Investor Centre
    • ASX Announcements
    • Financial Reports
      • Annual
      • Half-year
      • Quarterly
    • Corporate Directory
    • Shareholder services
    • Rights Issue
    • Top 40 Shareholders
    • Top 40 Option Holders
    • Corporate Governance
    • Corporate Presentations
  • Contacts

2024

Quarterly Report 31 March 2024

26 April 2024 by Audrey Thomson

Quarterly Report 31 March 2024

Categories 2024, ASX Announcements, Quarterly Reports

Report on Activities for the Quarter ended 31 March 2024

26 April 2024 by Audrey Thomson

Report on Activities for the Quarter Ended 31 March 2024

Categories 2024, ASX Announcements

Positive Outcomes in BIT225 Phase 2 Clinical Trial in HIV-1 (BIT225-010)

5 April 2024 by Audrey Thomson

Positive Outcomes in BIT225 Phase 2 Clinical Trial in HIV (BIT225-010)

Categories 2024, ASX Announcements

Half-year Report 31 December 2023

27 February 2024 by Audrey Thomson

Half-year Report 31 December 2023

Categories 2024, ASX Announcements, Half-year reports

R&D Tax Incentive

8 February 2024 by Audrey Thomson

R&D Tax Incentive

Categories 2024, ASX Announcements

Report on Activities for the Quarter ended 31 December 2023

30 January 2024 by Audrey Thomson

Report on Activities for the Quarter Ended 31 December 2023

Categories 2024, ASX Announcements

Quarterly Report 31 December 2023

30 January 2024 by Audrey Thomson

Quarterly Report 31 December 2023

Categories 2024, ASX Announcements, Quarterly Reports
Newer posts
← Previous Page1 Page2 Page3
© Biotron Limited 2016       ABN 60 086 399 144        Site updated 12 December 2025        Legal Notices and Privacy
Cleantalk Pixel